Clear All
11398 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
57881-0448-01 57881-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct 8, 2014 In Use
57881-0448-10 57881-0448 Ondansetron Zuplenz 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Oct 8, 2014 In Use
57884-2021-01 57884-2021 Letrozole Letrozole 2.5 mg/1 Hormonal Therapy Aromatase Inhibitor Oral May 16, 2013 In Use
57884-3021-00 57884-3021 Docetaxel Docetaxel 40.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous Feb 15, 2017 Oct 29, 2021 In Use
57894-0050-60 57894-0050 NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE AKEEGA 500.0 mg/1, 50.0 mg/1 Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP 17, PARP Oral Aug 11, 2023 In Use
57894-0080-60 57894-0080 Lazertinib LAZCLUZE 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
57894-0080-90 57894-0080 Lazertinib LAZCLUZE 80.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
57894-0100-60 57894-0100 NIRAPARIB TOSYLATE MONOHYDRATE and ABIRATERONE ACETATE AKEEGA 500.0 mg/1, 100.0 mg/1 Chemotherapy Androgen Receptor Inhibitor, Enzyme Inhibitor CYP17, PARP Oral Aug 11, 2023 In Use
57894-0111-01 57894-0111 ciltacabtagene autoleucel CARVYKTI 100000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Feb 28, 2022 In Use
57894-0111-02 57894-0111 ciltacabtagene autoleucel CARVYKTI 100000000.0 1/1 Immunotherapy CAR-T BCMA Intravenous Feb 28, 2022 In Use
57894-0150-12 57894-0150 Abiraterone Acetate Zytiga 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Apr 28, 2011 In Use
57894-0150-25 57894-0150 Abiraterone Acetate Zytiga 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Sep 1, 2015 Aug 31, 2018 In Use
57894-0155-12 57894-0155 Abiraterone acetate Abiraterone acetate 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Feb 9, 2018 In Use
57894-0184-12 57894-0184 Abiraterone Acetate Zytiga 250.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Apr 17, 2017 Apr 18, 2017 No Longer Used
57894-0195-06 57894-0195 Abiraterone Acetate Zytiga 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Apr 17, 2017 In Use
57894-0195-15 57894-0195 Abiraterone Acetate Zytiga 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Apr 17, 2017 In Use
57894-0199-06 57894-0199 Abiraterone acetate Abiraterone acetate 500.0 mg/1 Hormonal Therapy Androgen Receptor Inhibitor CYP17 Inhibitor Oral Mar 5, 2018 Sep 2, 2021 In Use
57894-0240-30 57894-0240 Lazertinib LAZCLUZE 240.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
57894-0240-99 57894-0240 Lazertinib LAZCLUZE 240.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Aug 20, 2024 In Use
57894-0420-01 57894-0420 Siltuximab Sylvant 100.0 mg/1 Immunotherapy Monoclonal Antibody Interleukin-6 Antagonists Intravenous Apr 23, 2014 Jan 31, 2021 No Longer Used
57894-0421-01 57894-0421 Siltuximab Sylvant 400.0 mg/1 Immunotherapy Monoclonal Antibody Interleukin-6 Antagonists Intravenous Apr 1, 2014 Jan 31, 2021 No Longer Used
57894-0449-01 57894-0449 Teclistamab TECVAYLI 10.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
57894-0450-01 57894-0450 Teclistamab TECVAYLI 90.0 mg/mL Immunotherapy Monoclonal Antibody BCMA, CD3 Subcutaneous Oct 25, 2022 In Use
57894-0469-01 57894-0469 Talquetamab TALVEY 3.0 mg/1.5mL Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 Subcutaneous Aug 9, 2023 In Use
57894-0470-01 57894-0470 Talquetamab TALVEY 40.0 mg/mL Immunotherapy T Cell Receptor (TCR) GPRC5D, CD3 Subcutaneous Aug 9, 2023 In Use

Found 11398 results — Export these results